Jump to content

Aripiprazole/sertraline

Add links
From Wikipedia, the free encyclopedia
Aripiprazole/sertraline
Combination of
AripiprazoleAtypical antipsychotic
SertralineSelective serotonin reuptake inhibitor
Clinical data
Other namesASC-01
Routes of
administration		By mouth
Legal status
Legal status

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).[1] It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole.[1][2] In July 2017, it was in preregistration in Japan for the treatment of MDD.[1] However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.[3]

See also

[edit]

References

[edit]
  1. ^ a b c "Aripiprazole/sertraline - Otsuka Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Kamdijima K, Kimura M, Kuwahara K, Kitayama Y, Tadori Y (August 2018). "Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder". Psychiatry and Clinical Neurosciences. 72 (8): 591–601. doi:10.1111/pcn.12663. PMID 29660207. S2CID 4958169.
  3. ^ "Aripiprazole/sertraline - Otsuka Pharmaceutical - AdisInsight". adisinsight.springer.com.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Aripiprazole/sertraline&oldid=1183561413"